A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are one of the preferred approved treatment options for people with type 2 diabetes (T2D) and inadequate glycaemic control. The objective of this review is to provide a general clinical overview of the similarities and differences in the mechanisms of action (MoA) of the once‐weekly GLP‐1 RA class of medications, highlighting the role of pharmacists in providing optimal medication management, education and care for people with diabetes.

• Publication year

  2020

• Venue

  Journal of Clinical Pharmacy and Therapeutics

• Publication date

  2020-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jcpt.13230PMID 32910490PMCID 7540167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents

  2020cited by this paper
• Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes

  2020cited by this paper
• Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD)

  2020cited by this paper
• SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

  2019cited by this paper
• Introduction: Standards of Medical Care in Diabetes—2020

  2019cited by this paper
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.

  2019cited by this paper
• 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2019cited by this paper
• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

  2019cited by this paper
• Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes

  2018cited by this paper
• Semaglutide for type 2 diabetes mellitus: A systematic review and meta‐analysis

  2018cited by this paper
• Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

  2018cited by this paper
• Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.

  2018cited by this paper
• GLP-1 Receptor Expression Within the Human Heart

  2018cited by this paper
• Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.

  2018cited by this paper
• Effect of once‐weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo‐controlled, double‐blind, crossover trial

  2018cited by this paper
• Differential effects of glucagon-like peptide-1 receptor agonists on heart rate

  2017cited by this paper
• Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

  2017cited by this paper
• Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.

  2017cited by this paper
• Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

  2017cited by this paper
• Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity

  2017cited by this paper
• Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.

  2017cited by this paper
• Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

  2017cited by this paper
• Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

  2017cited by this paper
• Immunohistochemical assessment of glucagon‐like peptide 1 receptor (GLP‐1R) expression in the pancreas of patients with type 2 diabetes

  2017cited by this paper
• Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis

  2017cited by this paper
• Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials

  2017cited by this paper
• The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy

  2017cited by this paper
• Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

  2017cited by this paper
• Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

  2017cited by this paper
• The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide

  2016cited by this paper
• Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

  2016cited by this paper
• Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments

  2016cited by this paper
• Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta‐analysis

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• Prevalence of Prediabetes and Abdominal Obesity Among Healthy-Weight Adults: 18-Year Trend

  2016cited by this paper
• Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

  2016cited by this paper
• Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• GLP-1 Agonists and Blood Pressure: A Review of the Evidence

  2016cited by this paper
• Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program

  2016cited by this paper
• Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

  2015cited by this paper
• Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.

  2015cited by this paper
• The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

  2015cited by this paper
• Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

  2015cited by this paper
• Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

  2015cited by this paper
• A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

  2015cited by this paper
• Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.

  2015cited by this paper
• Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance

  2015cited by this paper
• GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

  2014cited by this paper
• Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

  2014cited by this paper
• Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

  2014cited by this paper
• Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence

  2014cited by this paper
• Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.

  2014cited by this paper
• Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

  2014cited by this paper
• Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159–2167

  2014cited by this paper
• Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

  2014cited by this paper
• Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states.

  2014cited by this paper
• The potential for renoprotection with incretin-based drugs.

  2014cited by this paper
• Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes

  2014cited by this paper
• Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

  2013cited by this paper
• Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

  2013cited by this paper
• Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin

  2013cited by this paper
• The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes

  2013cited by this paper
• Adherence to Therapies in Patients with Type 2 Diabetes

  2013cited by this paper
• GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

  2013cited by this paper
• Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

  2013cited by this paper
• Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus

  2012cited by this paper
• GLP‐1 based therapies: differential effects on fasting and postprandial glucose

  2012cited by this paper
• GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

  2012cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

  2012cited by this paper
• The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors

  2012cited by this paper
• Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and its Association with Complications in Patients with type 2 Diabetes Mellitus

  2012cited by this paper
• Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

  2011cited by this paper
• Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

  2011cited by this paper
• DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

  2011cited by this paper
• Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

  2011cited by this paper
• DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

  2010cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

  2009cited by this paper
• The impact of medication regimen factors on adherence to chronic treatment: a review of literature

  2008cited by this paper
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Mechanisms of action of glucagon-like peptide 1 in the pancreas.

  2007cited by this paper
• Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

  2006cited by this paper
• Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites

  2003cited by this paper
• Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

  2002cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences

  1995cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper
• Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

  1993cited by this paper
• Glucagon-like peptide-1 7-36: a physiological incretin in man.

  1987cited by this paper
• rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

  year unknowncited by this paper

• The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome

  2026cites this paper
• The Multifaceted Nature of GLP-1: Molecular Mechanisms and Signaling Pathways in Metabolic and Neurodegenerative Diseases.

  2026cites this paper
• Progression to type 2 diabetes among post–myocardial infarction patients with overweight or obesity: a real-world cohort study

  2026cites this paper
• Beyond lifestyle modification: the role of GLP-1 receptor agonists in treating pediatric obesity

  2026cites this paper
• Pharmacogenomics-Guided therapeutics in type 2 diabetes: Mechanisms, drug Targets, and precision medicine perspectives

  2026cites this paper
• Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot.

  2026cites this paper
• Glycemic Outcomes of Oral Hypoglycemics Versus GLP-1 Receptor Agonists in Type 2 Diabetes: A Comparative Clinical Study

  2025cites this paper
• Global Mapping of Flavonoids in Fruits and Vegetables: Targeting Insulin Receptors, GLP‐1R, and PPARs to Mitigate Diabetes

  2025cites this paper
• In silico investigations of albumin-GLP-1 receptor agonist complexes for diabetes drug delivery applications

  2025cites this paper
• Cosmetic Considerations of Semaglutide

  2025cites this paper
• SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes

  2025cites this paper
• Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review

  2025cites this paper
• A comprehensive Review of the Multi-System Benefits of Anti-Diabetic Drug Classes in Aging Beyond Glycemic Control

  2025cites this paper
• From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson’s disease. A systematic review and meta-analysis of placebo-controlled trials

  2025cites this paper
• Evolution of multidisciplinary obesity treatments: past, present, and future role of nutrition

  2025cites this paper
• Re-imagining Oral Semaglutide in Routine Clinical Practice: Indian Expert Panel Recommendations

  2025cites this paper
• The effect of Semaglutide on mitochondrial function and insulin sensitivity in a myotube model of insulin resistance.

  2025cites this paper
• Increased Weight Loss With the Combination of Levoketoconazole and Semaglutide in a Patient With Mild Hypercortisolism

  2025cites this paper
• GLP-1 Receptor Agonists in Gastrointestinal Practices: Enhancing Both Procedural and Patient-Related Outcomes

  2025cites this paper
• Dual Conjugation of Long- and Medium-Chain Fatty Acids to BimBH3 Peptide Yields Ultra Long-Acting Inhibitors of Intracellular PTPN1/2.

  2025cites this paper
• A Validated, Stability-Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance.

  2025cites this paper
• Effects of berry consumption on cardiometabolic risk factors in patients with metabolic syndrome: a systematic review and meta-analysis of randomised controlled trials

  2025cites this paper
• Administration of Bifidobacterium animalis Subsp. lactis BLa80 and Lactobacillus acidophilus LA85 Improved Hyperglycemia and Modulated Gut Microbiota in Type 2 Diabetic Mice.

  2025cites this paper
• A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist

  2025cites this paper
• GLP-1R agonists: recent advances, current gaps, and future challenges

  2025cites this paper
• 2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide

  2025cites this paper
• Postoperative Outcomes in Body Contouring Procedures Following GLP-1 Receptor Agonist Use: A 10-Year Analysis.

  2025cites this paper
• Use of glucagon-like peptide-1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review.

  2025cites this paper
• Risk of Retinal Vein Occlusion between Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes

  2025cites this paper
• Comparison of the efficacy and safety of GLP‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis

  2025cites this paper
• Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis

  2025cites this paper
• Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes

  2025cites this paper
• Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence

  2025cites this paper
• Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center

  2025cites this paper
• Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation.

  2025cites this paper
• ADVERSE EFFECTS OF GLP-1 RECEPTOR AGONISTS: A COMPREHENSIVE APPROACH

  2025cites this paper
• Toxicity of Semaglutide upon sub chronic administration in Rabbits

  2025influential citation
• Traditional therapeutic practices of antidiabetic herbs in certain districts of Assam and their validation based on the Glycemic index (GI) evaluation of commonly used herbs

  2025cites this paper
• Prescribing Patterns and Adverse Effects of Semaglutide: A Real-World Comparative Evaluation

  2025cites this paper
• Severe Adverse Effects of Tirzepatide Overdose Requiring Intensive Care Unit Admission and Complex Rehabilitation

  2025cites this paper
• One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA

  2024cites this paper
• Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide.

  2024cites this paper
• Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus

  2024cites this paper
• Glucagon-like peptide-1 and interleukin-6 interaction in response to physical exercise: An in-silico model in the framework of immunometabolism

  2024cites this paper
• IDegLira for the real‐world treatment of type 2 diabetes in Italy. Final results from the REX observational study

  2024cites this paper
• Could the answer to NAFLD be hidden in diabetic therapy? The impact of T2DM treatment on NAFLD

  2024cites this paper
• G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?

  2024cites this paper
• Anti‐obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta‐analysis to inform the 2023 international evidence‐based guideline

  2024cites this paper
• Relationship between hyperleptinemia and cardiometabolic risk in persons with obesity

  2024cites this paper
• Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease

  2024cites this paper
• Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue.

  2024cites this paper
• Trial of Lixisenatide in Early Parkinson's Disease.

  2024cites this paper
• Existing and emerging GLP-1 receptor agonist therapy: Ramifications for diabetic retinopathy screening

  2024cites this paper
• Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes

  2024cites this paper
• Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials

  2024cites this paper
• Effects of Glucose and Lipid Metabolism and Visceral Fat in Overweight and Obese Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide Combined with Dapagliflozin

  2024cites this paper
• Do anti-obesity medical treatments have a direct effect on adipose tissue?

  2024cites this paper
• New Perspectives in Management of Cardiovascular Risk Among People With Diabetes

  2024cites this paper
• Unlocking the Potential: Semaglutide’s Impact on Alzheimer’s and Parkinson’s Disease in Animal Models

  2024influential citation
• To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists

  2024cites this paper
• Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism—A Narrative Review

  2024cites this paper
• Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future

  2024cites this paper
• Use of continuous glucose monitoring when initiating glucagon‐like peptide‐1 receptor agonist therapy in insulin‐treated diabetes

  2024cites this paper
• Semaglutide induced Pancreatitis

  2024cites this paper
• Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• Neuroprotective Activity of GLP-1 Analogues: General Understanding of Implementation Mechanisms

  2024cites this paper
• Advances in the Insulin–Heart Axis: Current Therapies and Future Directions

  2024cites this paper
• GLP-1 receptor agonist–induced diabetic ketoacidosis: A case report

  2024cites this paper
• Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies

  2024cites this paper
• Optimizing nutrition, diet, and lifestyle communication in GLP-1 medication therapy for weight management: A qualitative research study with registered dietitians

  2024cites this paper
• Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration

  2024cites this paper
• Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes

  2024cites this paper
• Long-Term clinical efficacy of liraglutide for type 2 diabetes: real-world evidence and outcomes from Pakistan

  2024cites this paper
• Spotlight on the Mechanism of Action of Semaglutide

  2024cites this paper
• Semaglutide (Ozempic ® ): a comprehensive review of its pharmacology, efficacy, and safety profile in type 2 diabetes mellitus and weight management

  2024cites this paper
• A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

  2023cites this paper
• Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study

  2023cites this paper
• The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes

  2023influential citation
• Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness – a narrative review

  2023cites this paper
• Efficacy of Fasting in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review

  2023influential citation
• Investigating the Binding Efficacy of Snake Venom Proteins as GLP-1 Analogs for Diabetes mellitus Management: An In silico Study

  2023cites this paper
• IMPACT OF SEMAGLUTIDE ON GLYCEMIC CONTROL AND POST-PRANDIAL GLUCOSE REDUCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

  2023cites this paper
• Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease.

  2023cites this paper
• Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study.

  2023cites this paper
• Pharmacotherapy before and after bariatric surgery.

  2023cites this paper
• The Utilization of Glucagon-like Peptide 1 Agonists and Risk of Following External Eye Diseases in Type 2 Diabetes Mellitus Individuals: A Population-Based Study

  2023cites this paper
• Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion

  2023cites this paper
• Real‐world study of the concomitant use of biphasic insulin aspart 30/70 with GLP‐1 receptor agonist versus first‐generation basal insulin with GLP‐1 receptor agonist in type 2 diabetes

  2023cites this paper
• Berry Dietary Interventions in Metabolic Syndrome: New Insights

  2023cites this paper
• Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy

  2022cites this paper
• Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes?—A Review of Intervention Studies

  2022cites this paper
• GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models.

  2022cites this paper
• Oral Glucose Tolerance Test for the Screening of Glucose Intolerance Long Term Post‐Heart Transplantation

  2022cites this paper
• Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications

  2022cites this paper
• Examining the evidence for weight management in individuals with type 2 diabetes

  2022influential citation
• Discovery and development of tricyclic matrinic derivatives as anti-diabetic candidates by AMPKα activation

  2022cites this paper
• Investigation of the Exometabolomic Profiles of Rat Islets of Langerhans Cultured in Microfluidic Biochip

  2022cites this paper
• Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms

  2022influential citation
• Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?

  2022cites this paper
• Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?

  2022cites this paper